Drugs / Nanocoll
last change Aug 2021 re-read 2 minutes ago

Nanocoll

Diagnostic / imaging agent

Investigated by
Anna Cruceta

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04261179 Mar 2020 → Feb 2021 breast cancer, malignant tumor of neck, melanoma Anna Cruceta Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Nanocoll ClinicalTrials.gov intervention name — accepted as the source's own label NCT04261179
Modality Diagnostic / imaging agent “for Image- Guided Sentinel Lymph Node Mapping” NCT04261179